270 related articles for article (PubMed ID: 27439331)
21. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
[TBL] [Abstract][Full Text] [Related]
22. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C.
Sasso M; Tengher-Barna I; Ziol M; Miette V; Fournier C; Sandrin L; Poupon R; Cardoso AC; Marcellin P; Douvin C; de Ledinghen V; Trinchet JC; Beaugrand M
J Viral Hepat; 2012 Apr; 19(4):244-53. PubMed ID: 22404722
[TBL] [Abstract][Full Text] [Related]
23. The role of Fibroscan in predicting the presence of varices in patients with cirrhosis.
Al-Hamoudi WK; Abdelrahman AA; Helmy A; Anil S; Khamis N; Arafah M; Alswat KA; Suwefy YM; Sanai FM; Al Faleh F; Abdo AA
Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1307-12. PubMed ID: 26193054
[TBL] [Abstract][Full Text] [Related]
24. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B.
Mi YQ; Shi QY; Xu L; Shi RF; Liu YG; Li P; Shen F; Lu W; Fan JG
Dig Dis Sci; 2015 Jan; 60(1):243-51. PubMed ID: 25194851
[TBL] [Abstract][Full Text] [Related]
25. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy.
Yilmaz Y; Yesil A; Gerin F; Ergelen R; Akin H; Celikel ÇA; Imeryuz N
Scand J Gastroenterol; 2014 May; 49(5):611-6. PubMed ID: 24611771
[TBL] [Abstract][Full Text] [Related]
26. The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice.
Yen YH; Chen JF; Wu CK; Lin MT; Chang KC; Tseng PL; Tsai MC; Lin JT; Hu TH
J Formos Med Assoc; 2017 Nov; 116(11):852-861. PubMed ID: 28888355
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B.
Wang CY; Lu W; Hu DS; Wang GD; Cheng XJ
World J Gastroenterol; 2014 Aug; 20(30):10585-90. PubMed ID: 25132779
[TBL] [Abstract][Full Text] [Related]
28. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study.
Ferraioli G; Tinelli C; Dal Bello B; Zicchetti M; Filice G; Filice C;
Hepatology; 2012 Dec; 56(6):2125-33. PubMed ID: 22767302
[TBL] [Abstract][Full Text] [Related]
29. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
Karlas T; Petroff D; Sasso M; Fan JG; Mi YQ; de Lédinghen V; Kumar M; Lupsor-Platon M; Han KH; Cardoso AC; Ferraioli G; Chan WK; Wong VW; Myers RP; Chayama K; Friedrich-Rust M; Beaugrand M; Shen F; Hiriart JB; Sarin SK; Badea R; Jung KS; Marcellin P; Filice C; Mahadeva S; Wong GL; Crotty P; Masaki K; Bojunga J; Bedossa P; Keim V; Wiegand J
J Hepatol; 2017 May; 66(5):1022-1030. PubMed ID: 28039099
[TBL] [Abstract][Full Text] [Related]
30. Quantification of Steatosis and Fibrosis using a new system implemented in an ultrasound machine.
Sporea I; Bâldea V; Lupușoru R; Bende F; Mare R; Lazăr A; Popescu A; Șirli R
Med Ultrason; 2020 Sep; 22(3):265-271. PubMed ID: 32399537
[TBL] [Abstract][Full Text] [Related]
31. How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis?
Trowell J; Alukal J; Zhang T; Liu L; Maheshwari A; Yoo HY; Thuluvath PJ
Dig Dis Sci; 2021 Apr; 66(4):1297-1305. PubMed ID: 32337667
[TBL] [Abstract][Full Text] [Related]
32. Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens).
Ferraioli G
J Med Ultrason (2001); 2021 Oct; 48(4):489-495. PubMed ID: 34132934
[TBL] [Abstract][Full Text] [Related]
33. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
[TBL] [Abstract][Full Text] [Related]
34. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?
Kumar M; Rastogi A; Singh T; Behari C; Gupta E; Garg H; Kumar R; Bhatia V; Sarin SK
J Gastroenterol Hepatol; 2013 Jul; 28(7):1194-201. PubMed ID: 23425053
[TBL] [Abstract][Full Text] [Related]
35. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.
Wong VW; Petta S; Hiriart JB; Cammà C; Wong GL; Marra F; Vergniol J; Chan AW; Tuttolomondo A; Merrouche W; Chan HL; Le Bail B; Arena U; Craxì A; de Lédinghen V
J Hepatol; 2017 Sep; 67(3):577-584. PubMed ID: 28506907
[TBL] [Abstract][Full Text] [Related]
36. Ultrasound-Based Quantification of Fibrosis and Steatosis with a New Software Considering Transient Elastography as Reference in Patients with Chronic Liver Diseases.
Popa A; Șirli R; Popescu A; Bâldea V; Lupușoru R; Bende F; Cotrău R; Sporea I
Ultrasound Med Biol; 2021 Jul; 47(7):1692-1703. PubMed ID: 33832824
[TBL] [Abstract][Full Text] [Related]
37. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease.
Shen F; Zheng RD; Shi JP; Mi YQ; Chen GF; Hu X; Liu YG; Wang XY; Pan Q; Chen GY; Chen JN; Xu L; Zhang RN; Xu LM; Fan JG
Liver Int; 2015 Nov; 35(11):2392-400. PubMed ID: 25689614
[TBL] [Abstract][Full Text] [Related]
38. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.
Petroff D; Blank V; Newsome PN; Shalimar ; Voican CS; Thiele M; de Lédinghen V; Baumeler S; Chan WK; Perlemuter G; Cardoso AC; Aggarwal S; Sasso M; Eddowes PJ; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Cobbold JF; Naveau S; Lupsor-Platon M; Mueller S; Krag A; Irles-Depe M; Semela D; Wong GL; Wong VW; Villela-Nogueira CA; Garg H; Chazouillères O; Wiegand J; Karlas T
Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):185-198. PubMed ID: 33460567
[TBL] [Abstract][Full Text] [Related]
39. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations.
de Lédinghen V; Vergniol J; Capdepont M; Chermak F; Hiriart JB; Cassinotto C; Merrouche W; Foucher J; Brigitte le B
J Hepatol; 2014 May; 60(5):1026-31. PubMed ID: 24378529
[TBL] [Abstract][Full Text] [Related]
40. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD.
Friedrich-Rust M; Romen D; Vermehren J; Kriener S; Sadet D; Herrmann E; Zeuzem S; Bojunga J
Eur J Radiol; 2012 Mar; 81(3):e325-31. PubMed ID: 22119555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
